Every Form 4 that Haemonetics Corporation (HAE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HAE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HAE filings page.
Madaus Martin D reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corp director Martin D. Madaus received a grant of 2,538 restricted stock units under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan on July 24, 2026. The RSUs vest 100% on the first anniversary of the grant date, with each unit delivering one share of common stock and 2,538 shares reported as directly owned after the award.
Zane Ellen M reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corporation director Ellen M. Zane received a grant of 2,538 restricted stock units under the company’s Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, and her direct common stock holdings total 21,911 shares after the award.
Pomeroy Claire reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corp director Claire Pomeroy reported a grant of 2,538 restricted stock units (RSUs) under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan on 2026-07-24. The RSUs vest 100% on the first anniversary of the grant date, with each RSU delivering one share of common stock upon vesting. After this award, her direct holdings total 19,410 shares of common stock.
KROLL MARK W reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corp director Mark W. Kroll reported an equity award of 2,538 restricted stock units (RSUs) granted under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, with each RSU representing a contingent right to receive one (1) share of common stock when vested. Following this award, his reported direct holdings are 27,295 common shares, including these RSUs.
Haemonetics Corp director Lloyd Emerson Johnson reported an equity compensation award of 2,538 shares of common stock in the form of restricted stock units (RSUs) on 2026-07-24. The RSUs vest 100% on the first anniversary of the grant date, with each RSU converting into one share of common stock when vested.
After this grant, Johnson’s directly held common stock position was reported as 15,471 shares.
COYLE MICHAEL J reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corp director Michael J. Coyle received an equity award of 2,538 restricted stock units (RSUs) tied to the company’s common stock on 2026-07-24 under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, with each RSU representing a contingent right to receive one share of common stock when vested. Following this award, Coyle directly holds 17,932 shares of Haemonetics common stock.
Bryant Diane M reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corp director Diane M. Bryant received a grant of 2,538 restricted stock units on July 24, 2026 under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, and each unit represents a contingent right to receive one share of common stock when vested. Following this award, Bryant holds 9,664 shares of Haemonetics common stock directly.
ABERNATHY ROBERT E reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corp director Robert E. Abernathy received a grant of 2,538 restricted stock units (RSUs) on 2026-07-24 under the Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% one year after grant, each into one share of common stock, bringing his direct holdings to 27,519 shares.
Haemonetics Corp executive Maryanne Maunsell Farris, the VP and Chief Accounting Officer, reported an automatic share disposition tied to equity compensation. On the RSU vesting date, 259 shares of common stock were withheld at $71.28 per share to cover tax obligations, rather than sold on the open market. After this tax-withholding event, she beneficially owns 6,242 common shares, a figure that includes previously reported unvested restricted stock units.
Haemonetics Corp senior vice president of human resources Laurie A. Miller reported a small share disposition related to taxes. On the vesting of previously granted restricted stock units, 313 shares of common stock were withheld at a price of $71.28 per share to cover tax obligations. After this tax-withholding event, Miller directly holds 40,987 shares of Haemonetics common stock, which includes unvested restricted stock units.
Haemonetics Corporation EVP and General Counsel Michelle L. Basil reported routine equity compensation activity. She received a grant of 28,424 restricted stock units, each convertible into one share of common stock, under the company’s 2019 long-term incentive plan. The RSUs vest over three years, with 40% vesting on each of the first two anniversaries of the grant date and 20% on the third.
The filing also shows 2,913 shares of common stock withheld at $56.29 per share to satisfy tax obligations tied to previously granted RSUs, which is not an open-market sale. After these transactions, she directly holds 68,829 shares of common stock, including unvested RSUs.
Haemonetics EVP and COO Frank Chan received an equity award and had shares withheld for taxes. On May 15, 2026, he was granted 27,535 restricted stock units (RSUs) under the company’s long-term incentive plan. Each RSU represents a right to receive one share of common stock when it vests.
The RSUs vest over three years, with 40% vesting on the first anniversary of the grant date, another 40% on the second anniversary, and the remaining 20% on the third anniversary. On the same date, 546 shares were disposed of at $56.29 per share to satisfy tax obligations related to vesting of previously granted RSUs, rather than through an open-market sale.
After these transactions, Chan directly owned 32,936 shares of Haemonetics common stock. This figure includes unvested RSUs and shares acquired through the Haemonetics Corporation 2007 Employee Stock Purchase Plan, including 139 shares bought on October 31, 2025 and 119 shares bought on April 30, 2026.
Haemonetics Corporation EVP and CFO James DArecca reported a new equity compensation grant. He received 29,312 shares of common stock in the form of restricted stock units (RSUs) at no cash cost, increasing his direct equity-based position.
In a related transaction, 2,505 shares were withheld at a market price of $56.29 per share to cover tax obligations tied to RSU vesting, which is not an open-market sale. After these transactions, he directly holds 54,444 shares, a figure that includes previously reported unvested RSUs.
The RSU award was granted under Haemonetics’ Amended and Restated 2019 Long-Term Incentive Compensation Plan. The units vest in three annual installments, with 40% vesting on each of the first two anniversaries of the grant date and the remaining 20% vesting on the third anniversary. Each RSU converts into one share of common stock upon vesting.
Haemonetics Corp VP and Chief Accounting Officer Maryanne Maunsell Farris received a grant of 2,220 restricted stock units, each representing one share of common stock vesting in three equal annual installments. In connection with RSU vesting, 197 shares were withheld to cover tax obligations, leaving her with 6,501 directly held shares, including unvested RSUs.
Haemonetics EVP and Chief Commercial Officer Roy Galvin reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. He received a grant of 27,535 shares of common stock in the form of RSUs under the company’s long-term incentive plan. These RSUs vest over three years, with 40% vesting on each of the first two anniversaries of the grant date and 20% on the third anniversary. On the same date, 879 shares valued at $56.29 per share were withheld to cover tax obligations tied to vesting RSUs, rather than sold on the open market. Following these transactions, he directly holds 39,882 shares of common stock, a figure that includes unvested RSUs previously reported and 415 shares acquired through the Haemonetics Corporation 2007 Employee Stock Purchase Plan.
Haemonetics Corp senior vice president of human resources Laurie A. Miller reported routine equity compensation activity involving company common stock. She received a grant of 13,323 shares valued at zero cost to her, reflecting the vesting or award of restricted stock units under the company’s long-term incentive plan.
In a related move, 948 shares at $56.29 each were withheld to cover tax obligations tied to the RSU vesting, a non-market transaction rather than an open-market sale. After these transactions, she directly holds 41,300 shares of Haemonetics common stock.
Haemonetics Corp President & CEO Christopher Simon reported compensation-related equity activity. He received an award of 78,344 shares of common stock in the form of restricted stock units that vest over three years. On the same date, 9,681 shares were withheld to cover tax obligations tied to previously vesting RSUs, and his reported direct holdings after these transactions were in the hundreds of thousands of shares.
Haemonetics EVP and CFO James DArecca reported a small tax-related share disposition. On May 1, 2026, 655 shares of Haemonetics common stock were withheld at $59.26 per share to cover tax obligations from vesting restricted stock units. This was not an open-market sale. After the withholding, DArecca directly owned 27,637 shares, which includes previously reported unvested RSUs.
Haemonetics (HAE) reported an insider share purchase on Form 4. A company director bought 1,400 shares of common stock at $70.56 on 11/10/2025. Following the transaction, the director’s direct beneficial ownership stands at 24,757 shares.
The ownership figure includes unvested restricted stock units that were previously reported. This filing records an open-market purchase by a board member and updates the director’s total holdings.
Haemonetics (HAE) disclosed an insider Form 4 for its EVP, Chief Commercial Officer. On 10/31/2025, 145 shares of common stock were withheld for taxes upon RSU vesting (code F) at $50.01 per share. Following this transaction, the reporting person directly beneficially owns 12,811 shares. This total includes unvested RSUs and 24 shares acquired under the company’s Employee Stock Purchase Plan on October 31, 2025.